WallStreetZenWallStreetZen

NASDAQ: KLRS
Kalaris Therapeutics Inc Stock Ownership - Who owns Kalaris Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Kalaris Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Srinivas AkkarajuDirector2026-05-20244,300$4.83
$1.18MBuy
Brett R. HagenChief Accounting Officer2026-03-201,915$6.72
$12.87kSell
Srinivas AkkarajuDirector2025-12-221,500,000$10.00
$15.00MBuy
Srinivas AkkarajuDirector2025-12-18479,847$10.42
$5.00MBuy

1 of 1

KLRS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KLRS insiders and whales buy or sell their stock.

KLRS Shareholders

What type of owners hold Kalaris Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Morana Jovanembiricos333.97%79,502,507$214.66MInsider
David Hallal292.80%69,701,844$188.19MInsider
Vikas Sinha143.35%34,123,650$92.13MInsider
Ansbert Gadicke126.55%30,125,933$81.34MInsider
Elevatebio LLC70.05%16,674,766$45.02MInsider
Gilead Sciences Inc69.88%16,635,286$44.92MInsider
Srinivas Akkaraju54.27%12,919,098$34.88MInsider
Samsara Biocapital GP LLC48.09%11,448,081$30.91MInsider
F2 Mg Ltd41.29%9,828,091$26.54MInsider
John Robert Wilson36.66%8,727,908$23.57MInsider

1 of 3

KLRS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KLRS0.01%99.99%Net Buying
PLRX0.08%42.31%Net Selling
GUTS0.04%18.42%Net BuyingNet Buying
FRMM0.02%99.98%Net SellingNet Selling
INKT0.00%100.00%Net BuyingNet Buying
View Top Biotech Stocks

Kalaris Therapeutics Stock Ownership FAQ

Who owns Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ: KLRS) is owned by 0.08% institutional shareholders, 1,255.23% Kalaris Therapeutics insiders, and 0.00% retail investors. Morana Jovanembiricos is the largest individual Kalaris Therapeutics shareholder, owning 79.50M shares representing 333.97% of the company. Morana Jovanembiricos's Kalaris Therapeutics shares are currently valued at $214.66M.

If you're new to stock investing, here's how to buy Kalaris Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.